Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 

Versions (1) ▾
  1. 3/15/19
Copyright Holder:
GSK group of companies
Uploaded on:

March 15, 2019

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369

Quality of Life

  1. StudyEvent: ODM
    1. Quality of Life
Administrative data
Physical well-being
Social/Family Well-Being
Emotional Well-Being
Functional Well-Being
Additional Concerns
Brief Pain Inventory
Brief Pain Inventory
Pain Interference